Compare Stocks: AVTE, STOK, MAZE, and QURE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.00 -2.7%	$18.77	$89.95 ▼ $99.05	$405.79M	0.95	53,591 shs	1.36 million shs
MAZE Maze Therapeutics	$26.66 -3.8%	$26.84	$21.95 ▼ $53.65	$1.54B	2.16	945,972 shs	615,138 shs
QURE uniQure	$21.28 -2.6%	$40.67	$8.73 ▼ $71.50	$1.51B	1.06	3.56 million shs	2.49 million shs
STOK Stoke Therapeutics	$22.50 -6.8%	$29.13	$20.32 ▼ $40.22	$1.56B	1.26	1.02 million shs	617,938 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-2.71%	-0.50%	-21.74%	-34.40%	+54.19%
MAZE Maze Therapeutics	-3.75%	+0.87%	+8.37%	-9.29%	-6.69%
QURE uniQure	-2.56%	-7.72%	-52.19%	-48.10%	-65.69%
STOK Stoke Therapeutics	-6.83%	-7.67%	-22.49%	-24.77%	-25.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.00 -2.7%	$18.77	$89.95 ▼ $99.05	$405.79M	0.95	53,591 shs	1.36 million shs
MAZE Maze Therapeutics	$26.66 -3.8%	$26.84	$21.95 ▼ $53.65	$1.54B	2.16	945,972 shs	615,138 shs
QURE uniQure	$21.28 -2.6%	$40.67	$8.73 ▼ $71.50	$1.51B	1.06	3.56 million shs	2.49 million shs
STOK Stoke Therapeutics	$22.50 -6.8%	$29.13	$20.32 ▼ $40.22	$1.56B	1.26	1.02 million shs	617,938 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-2.71%	-0.50%	-21.74%	-34.40%	+54.19%
MAZE Maze Therapeutics	-3.75%	+0.87%	+8.37%	-9.29%	-6.69%
QURE uniQure	-2.56%	-7.72%	-52.19%	-48.10%	-65.69%
STOK Stoke Therapeutics	-6.83%	-7.67%	-22.49%	-24.77%	-25.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MAZE Maze Therapeutics	3.08	Buy	$63.40	137.81% Upside
QURE uniQure	2.75	Moderate Buy	$53.73	152.48% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	96.67% Upside

Current Analyst Ratings Breakdown

Latest AVTE, STOK, MAZE, and QURE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	QURE uniQure	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Overweight ➝ Equal Weight	$60.00 ➝ $28.00
10/2/2026	QURE uniQure	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$65.00 ➝ $48.00
9/30/2026	QURE uniQure	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$46.00 ➝ $31.00
9/29/2026	QURE uniQure	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$75.00
9/29/2026	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$48.00
9/23/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/22/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$46.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MAZE Maze Therapeutics	$167.50M	8.84	N/A	N/A	$7.38 per share	3.61
QURE uniQure	$16.10M	91.69	N/A	N/A	$3.19 per share	6.67
STOK Stoke Therapeutics	$184.42M	7.87	N/A	N/A	$6.17 per share	3.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest AVTE, STOK, MAZE, and QURE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	QURE uniQure	-$0.9217	N/A	N/A	N/A	$6.21 million	N/A
11/3/2026	Q3 2026	STOK Stoke Therapeutics	-$0.9291	N/A	N/A	N/A	$8.21 million	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MAZE Maze Therapeutics	0.09	18.31	18.31
QURE uniQure	0.15	10.01	10.01
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
MAZE Maze Therapeutics	N/A
QURE uniQure	78.83%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
MAZE Maze Therapeutics	5.30%
QURE uniQure	4.65%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
QURE uniQure	221	69.37 million	66.14 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

AVTE, STOK, MAZE, and QURE Headlines

Recent News About These Companies

Stoke Therapeutics, Inc. Presents Data Supporting Disease-Modifying Potential Of STK-002 In Autosomal Dominant Optic Atrophy At The American Academy Of Ophthalmology 2026 ...

October 13 at 7:23 PM | marketscreener.comM

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)

October 13 at 7:23 PM | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?

October 13 at 2:59 PM | marketbeat.com

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO ...

October 12 at 1:41 PM | finance.yahoo.com

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

October 10, 2026 | finance.yahoo.com

Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting

October 6, 2026 | marketscreener.comM

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...

October 6, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?

October 6, 2026 | marketbeat.com

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 6, 2026 | businesswire.com

Stoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For Zorevunersen

October 5, 2026 | marketscreener.comM

Stoke Therapeutics stock heads into November 3 results below key averages

October 5, 2026 | ad-hoc-news.deA

Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock

October 3, 2026 | insidertrades.com

Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

October 2, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock

October 2, 2026 | marketbeat.com

Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 27, 2026 | marketbeat.com

Stoke Therapeutics, Inc. Announces Board Changes

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...

September 23, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, STOK, MAZE, and QURE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$14.00 -0.39 (-2.71%)

As of 10/12/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Maze Therapeutics NASDAQ:MAZE

$26.66 -1.04 (-3.75%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$26.30 -0.36 (-1.37%)

As of 08:54 AM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

uniQure NASDAQ:QURE

$21.28 -0.56 (-2.56%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$21.50 +0.22 (+1.03%)

As of 09:00 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stoke Therapeutics NASDAQ:STOK

$22.50 -1.65 (-6.83%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$22.39 -0.11 (-0.50%)

As of 08:53 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, STOK, MAZE, and QURE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, STOK, MAZE, and QURE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, STOK, MAZE, and QURE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, STOK, MAZE, and QURE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Maze Therapeutics NASDAQ:MAZE

uniQure NASDAQ:QURE

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, STOK, MAZE, and QURE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, STOK, MAZE, and QURE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, STOK, MAZE, and QURE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, STOK, MAZE, and QURE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Maze Therapeutics NASDAQ:MAZE

uniQure NASDAQ:QURE

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools